Login | Users Online: 753  
Home Print this page Email this page Small font sizeDefault font sizeIncrease font size   
Home | About us | Editorial board | Search | Ahead of print | Current Issue | Archives | Submit article | Instructions | Subscribe | Advertise | Contact us

    Article Cited by others


PCSK9 monoclonal antibodies: An overview

Kaddoura Rasha, Orabi Bassant, Salam Amar M

Year : 2020| Volume: 21| Issue : 2 | Page no: 97-103

   This article has been cited by
1 Inclisiran: a new generation of lipid-lowering siRNA therapeutic
Yanzhen Zhang, Huaigang Chen, Lang Hong, Hong Wang, Bin Li, Mengyin Zhang, Jiamei Li, Liu Yang, Fan Liu
Frontiers in Pharmacology. 2023; 14
[Pubmed]  [Google Scholar] [DOI]
2 Plasma Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) as a Possible Biomarker for Severe COVID-19
Patricia Mester, Pablo Amend, Stephan Schmid, Martina Müller, Christa Buechler, Vlad Pavel
Viruses. 2023; 15(7): 1511
[Pubmed]  [Google Scholar] [DOI]
3 Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations
Isabella Hetherington, Hana Totary-Jain
Molecular Therapy. 2022;
[Pubmed]  [Google Scholar] [DOI]


Read this article